AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bloomberg

Published November 9, 2026

J&J Backs Psychedelic -Inspired Biotech in $100 Million Round - Bloomberg.com

Read the full story at Bloomberg

It's the latest sign of big drugmakers' growing interest in the potential therapeutic benefits of psychedelics . The market for psychedelic medicines.

Post on X

Share this story

Surfaced by 3 Google Alerts

Psychedelics asia
Psychedelics
Psychedelic biotech